Predictive Biomarkers of Age-Related Macular Degeneration Response to Anti-VEGF Treatment
Open accessThe DOI matches its Crossref record; 78 of the 82 references it cites were found in a registry or an index.
Abstract
Age-related macular degeneration (AMD) is an incurable disease associated with aging that destroys sharp and central vision. Increasing evidence implicates both systemic and local inflammation in the pathogenesis of AMD. Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is currently the first-line therapy for choroidal neovascularization in AMD patients. However, a high number of patients do not show satisfactory responses to anti-VEGF treatment after three injections. Predictive treatment response models are one of the most powerful tools for personalized medicine. Therefore, the application of these models is very helpful to predict the optimal treatment for an early application on each patient. We analyzed the transcriptome of peripheral blood mononuclear cells (PBMCs) from AMD patients before treatment to identify biomarkers of response to ranibizumab. A classification model comprised of four mRNAs and one miRNA isolated from PBMCs was able to predict the response to ranibizumab with high accuracy (Area Under the Curve of the Receiver Operating Characteristic curve = 0.968), before treatment. We consider that our classification model, based on mRNA and miRNA from PBMCs allows a robust prediction of patients with insufficient response to anti-VEGF treatment. In addition, it could be used in combination with other methods, such as specific baseline characteristics, to identify patients with poor response to anti-VEGF treatment to establish patient-specific treatment plans at the first visit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Transcriptome analysis of peripheral blood mononuclear cells from 59 patients treated with ranibizumab demonstrated that the ranibizumab response could be predicted before treatment [39].”
From Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. (2024) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades
Friedländer, M. R., Mackowiak, S. D., Li, N., Chen, W., & Rajewsky, N. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr688 · Cited by 3,207
Data, information, knowledge and principle: back to metabolism in KEGG
Kanehisa, M., Goto, S., Sato, Y., Kawashima, M., Furumichi, M., & Tanabe, M. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1076 · Cited by 3,092
DIANA-miRPath v3.0: deciphering microRNA function with experimental support
Vlachos, I. S., Zagganas, K., Paraskevopoulou, M. D., Georgakilas, G., Karagkouni, D., Vergoulis, T., Dalamagas, T., & Hatzigeorgiou, A. G. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv403 · Cited by 1,699
Age-related macular degeneration
Fleckenstein, M., Keenan, T. D. L., Guymer, R. H., Chakravarthy, U., Schmitz-Valckenberg, S., Klaver, C. C., Wong, W. T., & Chew, E. Y. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00265-2 · Cited by 978
Data mining in bioinformatics using Weka
Frank, E., Hall, M., Trigg, L., Holmes, G., & Witten, I. H. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth261 · Cited by 882 · cited 1×
“To reduce the number of features to use, we performed a feature selection procedure (see Methods), using the Weka suite [41], on mRNA sequencing data from PBMCs obtained from the studied cohort.”
MethodLi, S., Rouphael, N., Duraisingham, S., Romero-Steiner, S., Presnell, S., Davis, C., Schmidt, D. S., Johnson, S. E., Milton, A., Rajam, G., et al. (2014) · Nature Immunology · doi:10.1038/ni.2789 · Cited by 770
Schmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., & Bandello, F. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 639 · cited 1×
“Anti-VEGF drugs are effective inhibitors of laser-induced CNV in animal models and they are the first line of therapy for wet AMD in humans [2,43].”
Background
Cited by
Genetic Aspects of Age-Related Macular Degeneration and Their Therapeutic Potential
Stradiotto, E., Allegrini, D., Fossati, G., Raimondi, R., Sorrentino, T., Tripepi, D., Barone, G., Inforzato, A., & Romano, M. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113280 · Cited by 29
Biomarkers as Predictive Factors of Anti-VEGF Response
Bobadilla, M., Pariente, A., Ana, I., Peláez, R., Pérez-Sala, Á., & Larráyoz, I. M. (2022) · Biomedicines · doi:10.3390/biomedicines10051003 · Cited by 33
“studied the transcriptomes from 59 wet AMD patients before undergoing ranibizumab treatment, and a set of miRNAs that were able to predict the ranibizumab response were identified [7].”
BackgroundMethodInfluentialSelf-citationCharacteristic Hallmarks of Aging and the Impact on Carcinogenesis
Fiore, M., Terracina, S. A., Ferraguti, G., Petrella, C., Bruno, S. M., Blaconà, G., Certo, M. G. D., Minni, A., Greco, A., Musacchio, A., et al. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220816120353 · Cited by 23
Kozhevnikova, O. S., Фурсова, А. Ж., Derbeneva, A. S., Nikulich, I. F., Сергеевич, Т. М., Devyatkin, V. A., Rumyantseva, Y. V., Telegina, D. V., & Kolosova, N. G. (2022) · Biomedicines · doi:10.3390/biomedicines10071658 · Cited by 17
“Inappropriate inflammatory responses have been linked to the pathogenesis of nAMD, and this might contribute to disease progression during anti-VEGF therapy treatment [18,23].”
BackgroundLalman, C., Yang, Y., & Walker, J. L. (2025) · Cells · doi:10.3390/cells14171315 · Cited by 30
“Using correlation-based feature selection and RF classification, they identified a panel of four mRNAs and one miRNA that predicted treatment response with high accuracy (AUC = 0.968), effectively distinguishing responders from non-responders before therapy initiation [146].”
InfluentialGarcía‐Hidalgo, M. C., Peláez, R., González, J., Santisteve, S., Benitez, I. D., Molinero, M., Perez‐Pons, M., Belmonte, T., Torres, G., Moncusí‐Moix, A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113617 · Cited by 11
“3 Illumina’s protocols (San Diego, CA, USA), as previously detailed [21, 22].”
Self-citationGenetics and Age-Related Macular Degeneration: A Practical Review for Clinicians.
Nguyen, J., Brantley, & Schwartz, S. G. (2024) · Frontiers in Bioscience-Scholar · doi:10.31083/j.fbs1601003 · Cited by 12
“Transcriptome analysis of peripheral blood mononuclear cells from 59 patients treated with ranibizumab demonstrated that the ranibizumab response could be predicted before treatment [39].”
BackgroundChen, K.-Y., Chan, H.-C., & Chan, C.-M. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-025-07593-x · Cited by 12
Moshtaghion, S. M., Locri, F., Reyes, Á. P., Plastino, F., Kvanta, A., Morillo-Sánchez, M. J., Rodríguez-de-la-Rúa-Franch, E., Gutiérrez‐Sánchez, E., Montero-Sánchez, A., Lucena-Padros, H., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083855 · Cited by 8
“An improved method to determine when re-administration of anti-VEGF injections is required to enhance treatment efficacy and avoid unnecessary doses [12,13].”
Zhang, X., Qiu, B., Gong, Z., Chen, X., Wang, Y., & Nie, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.946327 · Cited by 10
“Differently expressed mRNAs including ENSG00000249572, miRNA hasmiR-20a-5p in peripheral blood mononuclear cells found were to be predictors for good and poor responders to anti-VEGF therapy in patients with nAMD (35).”
BackgroundPariente, A., Pérez-Sala, Á., Ochoa, R., Bobadilla, M., Villanueva-Martínez, Á., Peláez, R., & Larráyoz, I. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087459 · Cited by 8
Self-citationTranscorneal electrical stimulation restores DNA methylation changes in retinal degeneration
Tew, B. Y., Gooden, G. C., Lo, P.-A., Pollalis, D., Ebright, B., Kalfa, A. J., Gonzalez-Calle, A., Thomas, B. B., Buckley, D. N., Simon, T., et al. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1484964 · Cited by 6
Yan, C., Yi, Q., Ge, L., Huang, Y., Yang, C., Lin, B., Jiang, D., & Zhou, M. (2025) · Eye and Vision · doi:10.1186/s40662-025-00444-2 · Cited by 5
“Although previous studies have investigated genomic and transcriptomic changes following anti-VEGF treatment [12–16], they do not fully capture the full biological complexity or the relationship between genotype and phenotype.”
García‐Quintanilla, L., Almuiña-Varela, P., Maroñas, O., Gil-Rodríguez, A., Rodríguez‐Cid, M. J., Gil‐Martínez, M., Abraldes, M. J., de Irazazabal, F. G.-U., González‐Barcia, M., Mondelo‐García, C., et al. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.13.34 · Cited by 6
“…the treatment response may be further be explored with studies that bridge the gap between genetic markers and clinical imaging biomarkers 56,57 more readily available to daily practice such as choroidal features such as choroidal thickness and perfusion index 58 or new OCT angiography…”
BackgroundPariente, A., Peláez, R., Ochoa, R., Pérez-Sala, Á., Villanueva-Martínez, Á., Bobadilla, M., & Larráyoz, I. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112590 · Cited by 4
Self-citationUppal, M., Hosseini, A., Bilal, K., Tan, N., Ai, Z., Khan, W., Samad, I., Gill, G., Yoo, H.-S., Chakravarthy, H., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1710965 · Cited by 3
“…been the primary therapeutic target for wet AMD; however, VEGF inhibitors, including a fl ibercept and ranibizumab, have only been effective for 50% patients and largely ineffective for 40-50% of patients; thus, anti-VEGF agents serve as symptomatic treatment rather than a method of prevention (10).”
Lin, J. B., Santeford, A. C., Usmani, D., Shah, A. V., Ruzycki, P. A., & Apte, R. S. (2023) · Ophthalmology Science · doi:10.1016/j.xops.2023.100410 · Cited by 5
“36 The results of the current work build on these past fi ndings by providing insight into the cell type-speci fi c gene expression signatures that may be associated with treatment response or burden.”
BackgroundProgress in single-cell sequencing of retinal vein occlusion or ischemic hypoxic retinopathy
Feng, Y., Wu, Y., Zhu, Y., He, Y., & Weng, W. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110436 · Cited by 3
Heloterä, H., Kostanek, J., Liukkonen, M., Siintamo, L., Linna-Kuosmanen, S., Watała, C. W., Błasiak, J., & Kaarniranta, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104852 · Cited by 2
“Additionally, the response to ranibizumab, an anti-VEGF drug, can be predicted from the miRNA and mRNA profiles of peripheral blood mononuclear cells [84].”
Intonti, S., Olivieri, C., Reibaldi, M., Borrelli, E., Curcio, C., & Conedera, F. M. (2025) · Biomolecules · doi:10.3390/biom15111571 · Cited by 5
“Moreover, the parallel findings in both animal models and human patients support the ongoing development of aqueous and vitreous fluid-based biomarkers for monitoring disease activity and therapeutic response in neovascular AMD [61,72].”
Experience with Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration
Budzinskaya, M. V., Plyukhova, A. A., Andreeva, Y. S., Kurguzova, A. G., & Budzinskaya, K. A. (2023) · Ophthalmology in Russia · doi:10.18008/1816-5095-2022-4-849-856 · Cited by 1
Rudeen, K. M., Maloney, C. M., Lydon, K. L., Teixeria, L. B. C., Mieler, W. F., & Kang‐Mieler, J. J. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.6.31 · Cited by 1
Aly, M. A. K. M., Mahrous, H., Desouky, L. M. I., & Nabil, K. M. (2023) · Delta Journal of Ophthalmology · doi:10.4103/djo.djo_64_22
Kang, H. M., Mendez, K. M., Laíns, I., Sourirajan, K., Bhat, R., Nigalye, A. K., Katz, R., Kozak, G., Choi, H., Bannerman, A., et al. (2025) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2025-002149
“1 Although anti-vascular endothelial growth factor (VEGF) agents are the standard of care treatment for nAMD, 2 there is a broad range of treatment responses in nAMD after anti-VEGF therapy, 3 and even with anti-VEGF therapy, visual outcomes may decline slowly with increased follow-up time.”
Camacho, P., Ribeiro, E., Pereira, B., Nascimento, J., Rosa, P. C., Henriques, J., Barrão, S., Afonso, J., Delgadinho, M., Ginete, C., et al. (2026) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2026.102681
“6,7 Early studies suggested that epigenetic changes may increase clus-terin secretion, a factor involved in drusen formation.”
Metadata
- Authors
- Oca, A. I., Pérez-Sala, Á., Pariente, A., Ochoa, R., Velilla, S., Peláez, R., & Larráyoz, I. M.
- Affiliations
- Biomarkers and Molecular Signaling Group, Center for Biomedical Research of La Rioja (CIBIR), Foundation Rioja Salud, 26006 Logroño, La Rioja, Spain
- Center for Biomedical Research of La Rioja (ES)
- Universidad de La Rioja (ES)
- Corresponding author
- Larráyoz, Ignacio M.
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2021-12-08
- Volume
- 11
- Issue
- 12
- Pages
- 1329
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC8706948
- OpenAlex
- W4200024873
- Cited by
- 25
- References
- 82
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 2 · 2023: 6 · 2022: 6
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- RIUR (Universidad de La Rioja) (submittedVersion, other-oa)
- Funders
- Instituto de Salud Carlos III (PI19/01805, CPII20/00029)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- age-related macular degeneration, anti-VEGF therapy, ranibizumab, predictive biomarkers, treatment response prediction, peripheral blood mononuclear cells, transcriptome, mRNA biomarkers, microRNA biomarkers, choroidal neovascularization, personalized medicine, inflammation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.